Imugene Limited's latest marketcap:
As of 06/22/2025, Imugene Limited's market capitalization has reached $67.43 M. According to our data, Imugene Limited is the 27260th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 67.43 M |
| Revenue (ttm) | -1,186,542 |
| Net Income (ttm) | -83,401,294.14 |
| Shares Out | 7.47 B |
| EPS (ttm) | -0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/28/2025 |
Imugene Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/22/2025 | A$67.43 M | -62.01% | 27260 |
| 12/31/2024 | A$275.18 M | -65.11% | 19976 |
| 12/29/2023 | A$788.6 M | -15.31% | 12527 |
| 12/30/2022 | A$931.15 M | -59.62% | 10781 |
| 12/31/2021 | A$2.31 B | 386.45% | 6852 |
| 12/31/2020 | A$474.09 M | 234.74% | 13447 |
| 12/31/2019 | A$141.63 M | 117.97% | 18176 |
| 12/31/2018 | A$64.98 M | 51.74% | 21460 |
| 12/29/2017 | A$42.82 M | 4.09% | 23468 |
| 12/30/2016 | A$41.14 M | 97.92% | 21752 |
Company Profile
About Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune systems of cancer patients, helping treat and eradicate tumors. Headquartered in Sydney, Australia, the company is dedicated to advancing cutting-edge treatments for various cancers.
Key Products Under Development
- Azer-cel: An allogeneic CAR T cell therapy currently in Phase 1 clinical trials for relapsed/refractory non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.
- CF33 VAXINIA: A combination of genomic sequences from vaccinia virus strains, in Phase 1 trials for advanced solid tumors.
- CF33 CD19: Chimeric antigen receptor T cell therapies targeting solid tumors, currently in Phase 1 studies.
- CF33 oncolytic virotherapy CHECKvacc: In Phase 1 trials for triple-negative breast cancer.
- HER-VAXX: A B-cell immunotherapy cancer vaccine that has completed Phase 2 trials for metastatic and advanced gastric cancer.
- PD1-Vaxx: A cancer vaccine designed to block PD-1 signaling, in Phase 2 trials for non-small cell lung cancer.
- NeoPOLEM: Currently in Phase 2 studies for MSI-high colorectal cancer.
Research Collaborations
Imugene has partnered with NeoImmuneTech to enhance the efficacy of cancer treatments through collaborative research efforts.
Frequently Asked Questions
-
What is Imugene Limited's (ASX-IMU) current market cap?As of 06/22/2025, Imugene Limited (including the parent company, if applicable) has an estimated market capitalization of $67.43 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Imugene Limited (ASX-IMU) rank globally by market cap?Imugene Limited global market capitalization ranking is approximately 27260 as of 06/22/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.